Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2015 1
2017 1
2018 3
2019 3
2020 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.
Hwang JH, Seo JH, Beshiri ML, Wankowicz S, Liu D, Cheung A, Li J, Qiu X, Hong AL, Botta G, Golumb L, Richter C, So J, Sandoval GJ, Giacomelli AO, Ly SH, Han C, Dai C, Pakula H, Sheahan A, Piccioni F, Gjoerup O, Loda M, Sowalsky AG, Ellis L, Long H, Root DE, Kelly K, Van Allen EM, Freedman ML, Choudhury AD, Hahn WC. Hwang JH, et al. Among authors: beshiri ml. Cell Rep. 2019 Nov 19;29(8):2355-2370.e6. doi: 10.1016/j.celrep.2019.10.068. Cell Rep. 2019. PMID: 31747605 Free PMC article.
Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
Adelaiye-Ogala R, Gryder BE, Nguyen YTM, Alilin AN, Grayson AR, Bajwa W, Jansson KH, Beshiri ML, Agarwal S, Rodriguez-Nieves JA, Capaldo B, Kelly K, VanderWeele DJ. Adelaiye-Ogala R, et al. Among authors: beshiri ml. Mol Cancer Ther. 2020 Jul;19(7):1436-1447. doi: 10.1158/1535-7163.MCT-19-0936. Epub 2020 May 5. Mol Cancer Ther. 2020. PMID: 32371590 Free PMC article.
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y. Marzi L, et al. Among authors: beshiri ml. Clin Cancer Res. 2019 Oct 15;25(20):6206-6216. doi: 10.1158/1078-0432.CCR-19-0419. Epub 2019 Aug 13. Clin Cancer Res. 2019. PMID: 31409613 Free PMC article.
A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KM, Yin J, Alilin AN, Karzai FH, Dahut WL, Corey E, Kelly K. Beshiri ML, et al. Clin Cancer Res. 2018 Sep 1;24(17):4332-4345. doi: 10.1158/1078-0432.CCR-18-0409. Epub 2018 May 10. Clin Cancer Res. 2018. PMID: 29748182 Free PMC article.
Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation.
Beshiri ML, Holmes KB, Richter WF, Hess S, Islam AB, Yan Q, Plante L, Litovchick L, Gévry N, Lopez-Bigas N, Kaelin WG Jr, Benevolenskaya EV. Beshiri ML, et al. Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18499-504. doi: 10.1073/pnas.1216724109. Epub 2012 Oct 23. Proc Natl Acad Sci U S A. 2012. PMID: 23093672 Free PMC article.
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Karzai F, VanderWeele D, Madan RA, Owens H, Cordes LM, Hankin A, Couvillon A, Nichols E, Bilusic M, Beshiri ML, Kelly K, Krishnasamy V, Lee S, Lee MJ, Yuno A, Trepel JB, Merino MJ, Dittamore R, Marté J, Donahue RN, Schlom J, Killian KJ, Meltzer PS, Steinberg SM, Gulley JL, Lee JM, Dahut WL. Karzai F, et al. Among authors: beshiri ml. J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2. J Immunother Cancer. 2018. PMID: 30514390 Free PMC article.
13 results